Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases.

Area of Science:

• Biotechnology
• Molecular Biology
• Pulmonology

Background:

• In vitro-transcribed messenger RNA (IVT mRNA) is emerging as a potent therapeutic modality for genetic diseases.
• Its applications span protein supplementation for absent or faulty proteins and vaccine development.
• Recent progress in in vivo lung delivery of mRNA has spurred interest in treating genetic lung diseases.

Purpose of the Study:

• To provide a comprehensive overview of cells implicated in various lung diseases.
• To review recent advancements in mRNA-based protein replacement therapy for genetic lung conditions.
• To summarize developments in mRNA modifications and nanocarrier systems for clinical applications.

Main Methods:

• Literature review of studies on IVT mRNA therapy.
• Analysis of mRNA modifications for enhanced expression, reduced immunogenicity, and increased stability.
• Examination of in vivo lung delivery systems for mRNA complexed with various carriers.
• Overview of cellular players in genetic lung diseases.

Main Results:

• IVT mRNA demonstrates significant potential for protein supplementation in genetic diseases.
• Numerous modifications have improved mRNA expression, stability, and reduced immunogenicity.
• Advancements in nanocarrier-based lung delivery systems are enabling in vivo mRNA applications.
• The review consolidates information on lung disease-associated cells and mRNA therapeutic strategies.

Conclusions:

• mRNA-based protein replacement therapy holds substantial promise for treating genetic lung diseases.
• Ongoing developments in mRNA technology and delivery systems are critical for clinical translation.
• Further research into mRNA modifications and effective nanocarriers is essential for therapeutic success.